author-photo

Marianne Just

Praxis

49

Papers

1068

Citations

Citation Trend

Filter By

Papers (35) Sort By

Journal Conference Others

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

2020 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (125)
Abstract GS3-01: Investigating denosumab as an add-on treatment to neoadjuvant chemotherapy and two different nab-paclitaxel schedules in a 2x2 design in primary breast cancer - First results of the GeparX study

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (5)
Differential impact of prognostic parameters in hormone receptor-positive lobular early breast cancer in the WSG PlanB trial

2020 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (1)
Influence of denosumab on disseminated tumor cells (DTC) in the bone marrow of breast cancer (BC) patients with neoadjuvant treatment: A GeparX translational substudy.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial: Evaluation of sCAIX as predictor in breast cancer

2019 International Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (8)
Comparison of an automated cartridge-based system for mRNA assessment with central immunohistochemistry in the neoadjuvant GeparX trial.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
188PDImpact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC)

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract GS3-05: Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer – GBG69

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (20)
Investigating Denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-Paclitaxel schedules – 2 × 2 factorial design (GeparX)

2018
Show All
- Source
- Cite
- Save
Citations (0)
Abstract P4-21-06: Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: A subanalysis of data from the randomized phase III GeparSepto trial

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)